CALDEIRÃO DE BOLSA

Aqui_Vale Escreveu: Quem é que por aqui está a negociar a NOVO em €uros, no Xetra, e como o faz?
No BPI, embora tenha o Xetra disponível, não tenho a NOVO, e não me resolvem a situação, andam a empurrar com a barriga, e estou a ficar farto.
CumPrim/
ValeAquilino

Títulos da farmacêutica dinamarquesa atingiram mínimos de julho de 2021.

Novo’s Wegovy pill close to matching injectable version in weight-loss trial

Danish drugmaker is racing to beat arch-rival Eli Lilly to market



Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/44ceb964-cb6 ... c2a26d4ba4

Novo Nordisk’s anti obesity pill has delivered almost as much weight loss as its Wegovy injectable in a new trial, as the Danish drugmaker races to beat arch-rival Eli Lilly to market with a tablet version of its blockbuster drug.

Patients taking Wegovy in pill form lost 16.6 per cent of their body weight over a 64-week phase 3 trial, just under the 17 per cent that patients taking the injection lost on average in a previous study. One in three participants taking the pill lost 20 per cent of their body weight. 

Ludovic Helfgott, Novo’s executive vice-president of product and portfolio strategy, said it was the first time that an oral and injectable weight-loss drug had been more or less at par. 

One problem with making the drug in tablet form is that the peptides — small strings of amino acids — in its active ingredient semaglutide are mostly broken down in the gut and do not make it into the bloodstream. Novo has added a compound that makes it easier for the drug to be absorbed in the stomach. 

Helfgott said the company was “increasingly convinced of the importance of an oral” to offer patients another way to take weight-loss drugs. “A few years ago, it was deemed impossible to put a peptide in a pill,” he added. 

Novo has lost ground to Lilly in the key US market, while investors have become concerned that its pipeline of next-generation weight-loss drugs is not as comprehensive. Its shares are down 60 per cent in the past year. 

Its obesity pill could help it win back market share. A decision on whether the US Food and Drug Administration will approve the drug is expected in the fourth quarter, whereas Lilly is slightly further behind in the process, with analysts expecting a decision from regulators next year.

Lilly has taken a different approach to its weight-loss pill, developing orforglipron from scratch with a compound it bought from Japan’s Chugai Pharmaceutical.

Results of the first major trial of orforglipron for obesity sent shares in Lilly down last month, after it reported average weight loss at the lower end of market expectations. The trial is not directly comparable to the latest Novo study.

Novo hopes that because the Wegovy pill has the same active ingredient as the injectable version, regulators and doctors will recognise the broader health benefits of both. Previous trials have found that injectable Wegovy causes a steep fall in the risk of serious cardiac events. 

Martin Holst Lange, Novo’s chief scientific officer, said semaglutide had “well established cardiovascular benefits”. 

Trial participants taking the Wegovy pill experienced similar side effects to those taking the injectable, with nausea and vomiting the most common problems.

Separately on Wednesday, Lilly published data showing orforglipron outperformed oral semaglutide for treating type 2 diabetes in a head-to-head trial.

Eli Lilly’s weight-loss pill meets target in key diabetes trial

Results from US pharma group show oral drug reduced body weight by 10.5% on average


US pharmaceutical group Eli Lilly has announced that the latest trial of its anti-obesity pill has met weight-loss targets, boosting its plans to seek approval for the drug as it fights for market dominance with rival Novo Nordisk.

Lilly said on Tuesday that its orforglipron pill reduced the body weight of people who were overweight and suffered from diabetes by 10.5 per cent on average. It noted that the side effects were similar to those for its injectable weight-loss drugs.

The results come after the market was disappointed earlier this month by the results of an orforglipron trial in people without diabetes: participants lost an average of 12.4 per cent of their body weight, at the lower end of expectations.

The results will intensify its long-running battle for market dominance with Novo Nordisk, which in May submitted its first weight-loss pill for US regulatory approval. Novo’s pill helped patients with diabetes lose about 9.2 per cent of their body weight at the highest dose in a trial.

(...)

Vendas do medicamento para a perda de peso Wegovy subiram 67% entre abril e junho.

How Novo Nordisk lost its lead in the weight loss race

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors


Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs.

But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then yesterday a major profit warning knocked more than €60bn off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.

Some in the industry think Novo’s core problem is quite simple: US rival Eli Lilly came up with a better product. Trials found more weight loss from Lilly’s Mounjaro and Zepbound than Ozempic and another Novo drug Wegovy, and anecdotally doctors report fewer side effects.

(...)

Novo Nordisk shares plunge after profit warning over US weight-loss copycats

Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy

Novo Nordisk has appointed Maziar Mike Doustdar as chief executive and president of the group as it slashed its sales and profit forecasts for the year amid stiff US competition for its blockbuster weight-loss drugs.

(...)

Jørgensen was ousted in May after shares in the company — the maker of Ozempic and Wegovy — fell more than 50 per cent in 12 months. Shares fell more than 26 per cent on Tuesday on the profit warning.

Novo, one of Europe’s largest companies by market capitalisation, said on Tuesday that sales in the first six months of the year rose 18 per cent after the effect of currency fluctuations were stripped out.

But it also warned that full-year sales growth was expected to be 8-14 per cent, sharply lower than its May estimate of 13-21 per cent.
Operating profit grew was up 29 per cent in the first half of the year but Novo said it now expects full-year growth of 10-16 per cent, down from previous estimates of 16-24 per cent.

“For Wegovy in the US, the sales outlook reflects the persistent use of compounded [copycat] GLP-1s, slower than expected market expansion and competition,” the company said.

Novo said in a statement it was pursuing litigation “to protect patients from copycat . . . drugs”.

(...)